Verapamil and nifedipine are effective in the treatment of angina pectoris. 1-3 Both drugs are described as calcium antagonists because they inhibit the slow calcium current in muscle cells thereby reducing the force of contraction of the myocardium and relaxing smooth muscle. These drugs may therefore be useful in the treatment of angina pectoris either because of a direct reduction in cardiac contractility,4 or as a result of the relaxation of vascular smooth muscle causing vasodilatation and afterload reduction,5 6 or through a combination of both mechanisms. Both verapamil7 and nifedipine8 have been shown to dilate coronary arteries, possibly resulting in increased myocardial oxygen supply, though in the case of nifedipine this view has been challenged.9 The relative effects on cardiac contractility, afterload reduction, and coronary vasodilatation of the two drugs have not been determined with certainty. A point of difference is that verapamil, but not nifedipine, has antiarrhythmic properties depressing atrioventricular node function.
0 Though these drugs have certain pharmacological similarities as well as differences, the clinical relevance in the treatment of patients with angina has not been established. This study was designed to make a direct comparison using exercise testing as an objective assessment. and was used as a measure of work capacity. The randomisation of treatment periods obviated a training effect. Patients had been familiarised previously with the exercise test. Sixteen point praecordial electrocardiograms were recorded with the patient in a sitting position before exercise and at 0, 1, 2, 3, 4, 5, 7, and 10 minutes after exercise. The electrodes were placed in a 4 by 4 grid over the left hemithorax. The boundaries of the grid were the second intercostal space superiorly, a line drawn horizontally 6 cm beneath the xiphisternum inferiorly, the left mid-axillary line, and the right sternal edge. Each tracing was analysed by an observer before the treatment code was broken, thereby excluding observer bias. Significant ST segment depression was considered to exist if there was a change of 1-0 mm or more, lasting for 0-08 s or longer.'4 Measurements of ST segment depression to the nearest 0 5 mm were made on three complexes for each praecordial point and the average taken. For each recording the sum of significant ST segment depression (.2ST) was calculated and used as an index of myocardial ischaemia. Resting and maximum exercise-induced heart rate were recorded. Systolic blood pressure was measured at rest and at minute intervals throughout exercise and the recovery period.
Results
Results are expressed as mean ± SEM and were compared using Student's paired t test. (Fig. la) .
GLYCERYL TRINITRATE CONSUMPTION
Both drugs reduced glyceryl trinitrate consumption compared with placebo (p<0 05) (Fig. lb) .
MAXIMAL WORK CAPACITY
In the placebo period maximal work capacity, expressed as VO2max, was 22-9± 15 ml/kg per min. Both drugs increased this value; verapamil to 26±1-4 ml/kg per min (p<0001) and nifedipine to 25-2±1-5 ml/kg per min (p<0005) (Fig. 1c) .
There was no significant difference in the effect on anginal attacks, glyceryl trinitrate consumption, and maximal work capacity between nifedipine and verapamil.
SYSTOLIC BLOOD PRESSURE
Resting systolic blood pressure was significantly reduced by both drugs. The control value of 147±5 mmHg was reduced by verapamil to 132±4 mmHg (p<O0005) and by nifedipine to 127±10 mmHg (p<00l).
The control value for maximal exercise-induced systolic blood pressure of 200±7 mmHg was reduced by nifedipine to 187±4 mmHIg (p<0 05), and by verapamil to 192±5 mmHg (not significant).
The systolic blood pressure for a given work load (the work capacity achieved during the control period) was significantly reduced by both drugs from the control value of 200±7 mmHg. Verapamil reduced the systolic blood pressure to 173±7 mmHg (p<0 005) and nifedipine reduced it to 168±6 mmHg (p<O0O1).
HEART RATE Verapamil produced a small but significant reduction in resting heart rate from 72±3 beats/min to 68±2 beats/min (p<0 05), whereas nifedipine tended to increase resting heart rate to 76±4 beats/min (not significant). The maximal exercise-induced heart rate of 122±5 beats/min was reduced by verapamil to 118±4 beats/min (not significant) and was increased by nifedipine to 132±4 beats/min (p<0c05).
ST SEGMENT CHANGES Fig. 2 shows the changes inEST with respect to time in the three treatment periods. "ST is maximal immediately, or soon after, exercise and gradually regresses to pre-exercise values after 10 minutes of recovery. Though there is a considerable increase in VO2max (that is increased exercise performance), .1ST (the "amount of myocardial ischaemia") in the verapamil and nifedipine treatment periods is unchanged from control values at all times. Our results show that both verapamil and nifedipine significantly increase work capacity (measured as VQ2max calculated from the duration of exercise on the treadmill) without changing the amount of myocardial ischaemia developed (as assessed by 2ST). After completion of the trial group.bmj.com on June 15, 2017 -Published by http://heart.bmj.com/ Downloaded from protocol, eight patients were given verapamil for one week and then exercised to the same work load as they achieved in the control period in the trial. The result (Fig. 3) illustrates that verapamil reduced the amount of ischaemia developed when the work load was fixed. Both drugs were found to reduce the frequency of anginal attacks and glyceryl trinitrate consumption. Systolic blood pressure, both at rest and when exercising to a given work load, was much reduced by both drugs. This agrees with previous studies on the haemodynamic effects of verapamil5 and nifedipine.6 It may explain the striking beneficial effects of both drugs, as afterload reduction enables the heart to use its available oxygen supply in performing useful volume work rather than energy consuming pressure work. 16 The effect of the two drugs on heart rate differed; nifedipine produced small rises in resting and maximal exercise-induced heart rate whereas verapamil tended to reduce both values. A fall in systolic blood pressure is normally accompanied by a reflex increase in heart rate, as was observed with nifedipine. Though verapamil produced a similar fall in systolic blood pressure to nifedipine, the expected reflex tachycardia was not observed. This suggests that verapamil, in contrast to nifedipine, has an additional negative chronotropic action that blocks the normal reflex increase in heart rate in response to a fall in systolic blood pressure.
The results show that side effects with nifedipine occur frequently. The most frequently recorded complaints were palpitation, pain in and swelling of the ankles, and indigestion. In contrast, verapamil was relatively free from side effects apart from constipation which was described by seven patients. Verapamil was not observed to prolong the PR interval in our patients. This well-recognised effect, however, is a contraindication to its use in conjunction with a beta-blocking agent in the treatment of supraventricular tachycardias'7 and is therefore potentially a major limitation to its usefulness in the treatment of angina. Nifedipine, in contrast, has been shown to be both safe and efficacious when used in conjunction with propranolol in the treatment of angina. 18 This study shows that both verapamil and nifedipine produce substantial benefit in the treatment of chronic stable angina. Though it can safely be used in conjunction with a beta-blocker, the high incidence of side effects with nifedipine limits its clinical usefulness, suggesting that verapamil may be the drug of choice when a calcium antagonist is to be used alone. A major reservation, however, is that it is not yet established that verapamil can be used safely in conjunction with a beta-blocking agent for the treatment of angina. 
